PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 12, 2016Journal of Lipid Research205 citationsOpen Access

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study

MKMarcin KrawczykMRMonika RauJSJörn M. Schattenberg

Key Result

The PNPLA3 variant was associated with increased steatosis (P=0.004) and fibrosis (P=0.042), whereas TM6SF2 was linked to steatosis (P=0.038) and MBOAT7 to fibrosis (P=0.021).

Study Design

Type

Cross-Sectional (n=515)

Multicenter

Yes

Structured PICO

Do the PNPLA3, TM6SF2, and MBOAT7 genetic variants modulate steatosis and fibrosis severity in patients with NAFLD?

P
Population
515 patients (54.4% female) aged 16-88 years with nonalcoholic fatty liver disease, 320 of whom underwent liver biopsy.
E
Exposure
PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 genetic variants
C
Comparator
Non-carriers or different genotypes
O
Outcome
NAFLD severity (steatosis and fibrosis grades)surrogate

The PNPLA3 variant increases risk for both steatosis and fibrosis, whereas TM6SF2 predominantly modulates hepatic fat accumulation and MBOAT7 is linked to fibrosis in NAFLD patients.

Abstract

The PNPLA3 p.I148M, TM6SF2 p.E167K, and MBOAT7 rs641738 variants represent genetic risk factors for nonalcoholic fatty liver disease (NAFLD). Here we investigate if these polymorphisms modulate both steatosis and fibrosis in patients with NAFLD. We recruited 515 patients with NAFLD (age 16-88 years, 280 female patients). Liver biopsies were performed in 320 patients. PCR-based assays were used to genotype the PNPLA3, TM6SF2, and MBOAT7 variants. Carriers of the PNPLA3 and TM6SF2 risk alleles showed increased serum aspartate aminotransferase and alanine transaminase activities (P 0.05). The MBOAT7 variant was solely associated with increased fibrosis (P = 0.046). In the multivariate model, variants PNPLA3 (P = 0.004) and TM6SF2 (P = 0.038) were associated with steatosis. Fibrosis stages were affected by the PNPLA3 (P = 0.042) and MBOAT7 (P = 0.021) but not by the TM6SF2 polymorphism (P > 0.05). The PNPLA3, TM6SF2, and MBOAT7 variants are associated with increased liver injury. The TM6SF2 variant seems to modulate predominantly hepatic fat accumulation, whereas the MBOAT7 polymorphism is linked to fibrosis. The PNPLA3 polymorphism confers risk of both increased steatosis and fibrosis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Krawczyk et al. (2016) conducted a cross-sectional in Nonalcoholic fatty liver disease (NAFLD) (n=515). PNPLA3, TM6SF2, and MBOAT7 genetic variants vs. Non-carriers was evaluated on Steatosis and fibrosis severity. The PNPLA3 variant was associated with increased steatosis (P=0.004) and fibrosis (P=0.042), whereas TM6SF2 was linked to steatosis (P=0.038) and MBOAT7 to fibrosis (P=0.021).

synapsesocial.com/papers/6a280b1b2413aa4ddcefb926https://doi.org/10.1194/jlr.p067454
Ask AI
Helpful
Bookmark
Share
View Full Paper